Large-scale testing (Phase 3)Ended earlyNCT02598297
What this trial is testing
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Who this might be right for
Myelofibrosis With High Molecular Risk Mutations
Novartis Pharmaceuticals 49